1037624-75-1 | R428

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$33.00	$23.00
2mg	95%	in stock	$50.00	$35.00
5mg	95%	in stock	$82.00	$57.00
10mg	95%	in stock	$122.00	$85.00
25mg	95%	in stock	$235.00	$164.00
50mg	95%	in stock	$301.00	$211.00
100mg	95%	in stock	$346.00	$242.00
250mg	95%	in stock	$606.00	$424.00
1g	95%	in stock	$1,746.00	$1,222.00

Description

• Catalog Number: AE11326
• Chemical Name: R428
• CAS Number: 1037624-75-1
• Molecular Formula: C30H34N8
• Molecular Weight: 506.6446
• MDL Number: MFCD21608463
• SMILES: N=c1nc([nH]n1c1nnc2-c3ccccc3CCCc2c1)Nc1ccc2c(c1)CC[C@H](CC2)N1CCCC1

Computed Properties

• Complexity: 775
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 38
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 5.5

Upstream Synthesis Route

The compound 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-[(7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl]-1H-1,2,4-triazole-3,5-diamine is a versatile building block in chemical synthesis. This complex molecule presents unique structural features that can be strategically utilized for the construction of novel pharmaceutical compounds and heterocyclic derivatives. Due to its diverse functional groups and intricate fused ring system, this compound can serve as a key intermediate for creating specialized drug candidates, agrochemicals, and materials with tailored properties. By incorporating this compound into synthetic pathways, chemists can access a wide range of molecular scaffolds and explore various chemical transformations to generate innovative compounds with potential applications in medicinal chemistry, material science, and other interdisciplinary fields.

Literature

• Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

  Cancer research 20150915

• Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.

  The Journal of investigative dermatology 20111201

• Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice.

  The Journal of pharmacology and experimental therapeutics 20110501

• The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.

  Blood 20110210

• The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

  Cancer biology & therapy 20101115

• R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

  Cancer research 20100215

• Pharmacological inhibition of Axl affects smooth muscle cell functions under oxidative stress.

  Vascular pharmacology 20100101